Probiotics and the intestinal tight junction barrier function

Disruption of the intestinal epithelial tight junction (TJ) barrier is a key pathogenic factor in numerous gastrointestinal (GI) disorders, including inflammatory bowel disease, irritable bowel syndrome, necrotizing enterocolitis, and enteric infections. The gut microbiota plays a pivotal role in regulating epithelial integrity, and emerging evidence highlights the therapeutic potential of probiotics in preserving or restoring TJ barrier function. This review summarizes the current literature on the protective effects of probiotics in modulating intestinal epithelial TJ barrier function. Specific strains of Lactobacillus, Bifidobacterium, Escherichia coli Nissle 1917, Bacillus subtilis, and Saccharomyces boulardii have been shown to enhance barrier integrity in cell culture, animal models, and in some clinical settings. These probiotics exert their effects through diverse mechanisms, including the upregulation of TJ proteins (e.g., occludin, claudins, ZO-1), suppression of proinflammatory cytokines, inhibition of NF-κB, myosin light chain kinase (MLCK) and MAPK signaling pathways, and activation of host pattern recognition receptors such as TLR-2 and PPARγ. Moreover, several studies highlight the strain-specific nature of these effects, underscoring the importance of identifying and characterizing individual probiotic strains for therapeutic use. Taken together, the data reviewed here support the potential of probiotics as adjunctive or preventive therapies targeting epithelial barrier dysfunction in a range of GI diseases. However, further mechanistic studies, clinical trials, and standardization of probiotic formulations are needed to translate these findings into effective, personalized interventions. This review highlights both the promise and complexity of probiotic-mediated intestinal barrier regulation and provides new insight for future research in this rapidly evolving field.